You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Biosimilars Implementation Evaluation Framework

Biosimilar biologic drugs, or “biosimilars”, are highly similar to reference biologic drugs. They are equally safe and effective treatment options but more cost-effective for the healthcare system. Provinces and territories across Canada have put in place approaches to support appropriate use of reference and biosimilar biologics.

In 2020, we led the development of an evaluation framework to assess the impact of these approaches on patients, providers and the healthcare system.

The intent of the evaluation framework is to support:

  • studying the effect of different approaches on:
    • drug utilization and uptake
    • cost savings
    • patient experiences and outcomes
  • assessments on education and resource needs

The result is a toolkit with a set of evaluation questions and indicators to measure the impacts of biosimilar funding policies and implementation strategies on patients, clinicians and drug programs.

This project was supported by the pan-Canadian Pharmaceutical Alliance (pCPA).